Department of Colorectal Surgery, General Hospital of Ningxia Medical University, Yinchuan, China; College of Clinical Medicine, Ningxia Medical University, Yinchuan, China.
Surgical Department, General Hospital of Ningxia Medical University, Yinchuan, China.
Nutrition. 2019 May;61:132-142. doi: 10.1016/j.nut.2018.10.038. Epub 2018 Nov 29.
The aim of the present study was to investigate the effects of prebiotics (containing fructooligosaccharides, xylooligosaccharides, polydextrose, and resistant dextrin) intake on immune function and intestinal microbiota structure in perioperative patients with colorectal cancer (CRC).
A randomized, double-blind, no-treatment parallel control clinical trial involving 140 perioperative patients (90 men and 50 women, aged 40-75 y) with CRC was performed. Patients were randomly divided into two groups: an intervention group (prebiotic group, n = 70) that received prebiotic supplementation of 30 g/d for 7 d, and a control group (non-prebiotic group, n = 70) that received no prebiotic supplementation. The nutritional and immunologic indices were evaluated for both groups before and after operation and analyzed against baseline values. Moreover, fecal samples were collected from 40 patients randomly chosen from the two groups to study intestinal microbiota, which was analyzed by sequencing the V3-V4 region of 16S ribosomal DNA using the Illumina (San Diego, CA) MiSeq (PE 2 × 300 bp) platform.
Oral intake of prebiotics produced significant effects on immunologic indices in both the preoperative and postoperative periods, but the patterns of effects were different. In the preoperative period, prebiotics increased serum levels of immunoglobulin G (IgG; P = 0.02), IgM (P = 0.00), and transferrin (P = 0.027; all P < 0.05). In the postoperative period, enhanced levels of IgG (P = 0.003), IgA (P = 0.007), suppressor/cytotoxic T cells (CD3CD8; P = 0.043), and total B lymphocytes (CD19; P = 0.012) were identified in the prebiotic group (all P < 0.05). The differences in the intestinal microbiota at the phylum level were not statistically significant between the intervention and control groups (P > 0.05). At the genus level, prebiotics increased the abundance of Bifidobacterium (P = 0.017) and Enterococcus (P = 0.02; both P < 0.05) but decreased the abundance of Bacteroides (P = 0.04) in the preoperative period (all P < 0.05). In the postoperative period, the abundance of Bacteroides (P = 0.04) was decreased, but the abundance of Enterococcus (P = 0.00), Bacillus (P = 0.01), Lactococcus (P = 0.00), and Streptococcus (P = 0.037) increased in the non-prebiotic group (all P < 0.05); however, no significant change was identified in the abundance of Enterococcus (P = 0.56), Lactococcus (P = 0.07), and Streptococcus (P = 0.56) as a result of prebiotic intervention in this period (all P > 0.05). The abundance of Escherichia-Shigella was increased after prebiotic intake in the postoperative period (P = 0.014, P < 0.05). There was a notable trend of decline in the abundance of intestinal microbiota from preoperative to postoperative in the non-prebiotic group.
Prebiotic intake is recommended to improve serum immunologic indicators in patients with CRC 7 d before operation. Prebiotics improved the abundance of four commensal microbiota containing opportunistic pathogens in patients with CRC. Surgical stress decreased the abundance of most intestinal microbiota in the intestinal tract but increased the abundance of some opportunistic pathogens and commensal microbiota. Bacteroides is a relevant bacterial species for further research on the mechanism of prebiotics.
本研究旨在探讨术前摄入益生元(含低聚果糖、木低聚糖、聚葡萄糖和抗性糊精)对结直肠癌(CRC)围手术期患者免疫功能和肠道微生物结构的影响。
进行了一项随机、双盲、无治疗平行对照的临床试验,涉及 140 例结直肠癌(CRC)围手术期患者(90 名男性和 50 名女性,年龄 40-75 岁)。患者随机分为两组:干预组(益生元组,n=70)接受 30 g/d 的益生元补充剂,共 7 d;对照组(非益生元组,n=70)不接受益生元补充。在术前和术后评估两组的营养和免疫指标,并与基线值进行分析。此外,从两组中随机选择 40 名患者采集粪便样本,使用 Illumina(圣地亚哥,CA)MiSeq(PE 2×300 bp)平台对 16S 核糖体 DNA 的 V3-V4 区进行测序,分析肠道微生物群。
术前和术后口服益生元对免疫指标均有显著影响,但影响模式不同。术前,益生元增加了血清免疫球蛋白 G(IgG;P=0.02)、IgM(P=0.00)和转铁蛋白(P=0.027;均 P<0.05)水平。术后,益生元组 IgG(P=0.003)、IgA(P=0.007)、抑制/细胞毒性 T 细胞(CD3CD8;P=0.043)和总 B 淋巴细胞(CD19;P=0.012)水平升高(均 P<0.05)。干预组和对照组在门水平上的肠道微生物群差异无统计学意义(P>0.05)。在属水平上,益生元增加了双歧杆菌(P=0.017)和肠球菌(P=0.02;均 P<0.05)的丰度,但降低了拟杆菌(P=0.04)的丰度在术前阶段(均 P<0.05)。术后,拟杆菌(P=0.04)的丰度降低,但肠球菌(P=0.00)、芽孢杆菌(P=0.01)、乳球菌(P=0.00)和链球菌(P=0.037)的丰度增加在非益生元组中(均 P<0.05);然而,在该时期由于益生元干预,肠球菌(P=0.56)、乳球菌(P=0.07)和链球菌(P=0.56)的丰度没有显著变化(均 P>0.05)。术后益生元摄入后大肠埃希菌-志贺菌的丰度增加(P=0.014,P<0.05)。非益生元组从术前到术后肠道微生物群的丰度呈明显下降趋势。
建议在术前 7 天摄入益生元以改善结直肠癌患者的血清免疫指标。益生元改善了结直肠癌患者四种含有机会性病原体的共生菌群的丰度。手术应激降低了肠道中大多数肠道微生物群的丰度,但增加了一些机会性病原体和共生菌群的丰度。拟杆菌是研究益生元机制的相关细菌种属。